U.S. patent application number 15/603741 was filed with the patent office on 2017-09-14 for oral pharmaceutical composition of isotretinoin.
The applicant listed for this patent is Sun Pharmaceutical Industries Limited. Invention is credited to Anuj Kumar FANDA, Satish Kumar JAIN, Rajesh RAO, Romi Barat SINGH.
Application Number | 20170258748 15/603741 |
Document ID | / |
Family ID | 55216820 |
Filed Date | 2017-09-14 |
United States Patent
Application |
20170258748 |
Kind Code |
A1 |
RAO; Rajesh ; et
al. |
September 14, 2017 |
ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN
Abstract
The present invention provides an oral pharmaceutical
composition of isotretinoin with reduced food effect. The present
invention further relates to a process for preparing the oral
pharmaceutical composition of the present invention.
Inventors: |
RAO; Rajesh; (Deoria,
IN) ; FANDA; Anuj Kumar; (Ghaziabad, IN) ;
JAIN; Satish Kumar; (Bilaspur, IN) ; SINGH; Romi
Barat; (Varanasi, IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Sun Pharmaceutical Industries Limited |
Mumbai |
|
IN |
|
|
Family ID: |
55216820 |
Appl. No.: |
15/603741 |
Filed: |
May 24, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14958398 |
Dec 3, 2015 |
9700535 |
|
|
15603741 |
|
|
|
|
PCT/IB2015/054101 |
May 29, 2015 |
|
|
|
14958398 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/26 20130101;
A61K 47/44 20130101; A61K 9/10 20130101; A61P 17/00 20180101; A61K
9/4866 20130101; A61P 1/04 20180101; A61K 9/16 20130101; A61K
9/0053 20130101; A61K 31/203 20130101; A61K 47/10 20130101; A61K
9/4833 20130101; A61K 31/202 20130101; A61K 31/07 20130101; A61P
29/00 20180101; A61K 9/4858 20130101; A61P 17/10 20180101; A61P
35/00 20180101; A61K 9/48 20130101; A61P 11/00 20180101; A61P 35/02
20180101; A61P 37/02 20180101; A61P 17/06 20180101 |
International
Class: |
A61K 31/202 20060101
A61K031/202; A61K 9/48 20060101 A61K009/48; A61K 9/00 20060101
A61K009/00; A61K 31/203 20060101 A61K031/203; A61K 31/07 20060101
A61K031/07; A61K 9/16 20060101 A61K009/16 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 31, 2014 |
IN |
2158/DEL/2014 |
Claims
1-33. (canceled)
34. An oral pharmaceutical composition comprising a micronized
isotretinoin having d90 value of not more than 30 microns, wherein
said composition is in the form of dispersion in a liquid vehicle
and exhibits a reduced food effect.
35. The oral pharmaceutical composition according to claim 34,
wherein said composition comprises a low dose isotretinoin in an
amount of about 36 mg, about 32 mg, about 28 mg, about 24 mg, about
20 mg, about 16 mg, or about 8 mg.
36. The oral pharmaceutical composition according to claim 34,
wherein said composition is further filled into capsules.
37. The oral pharmaceutical composition according to claim 34,
wherein the micronized isotretinoin has D.sub.90 less than 25
.mu.m, less than 20 .mu.m, less than 15 .mu.m, or less than 10
.mu.m.
38. The oral pharmaceutical composition according to claim 34,
wherein the micronized isotretinoin further has D.sub.50 is less
than 20 .mu.m, less than 15 .mu.m, less than 10 .mu.m, or less than
5 .mu.m.
39. The oral pharmaceutical composition according to claim 34,
wherein the micronized isotretinoin further has D.sub.10 is less
than 10 .mu.m, less than 8 .mu.m, less than 7 .mu.m, less than 5
.mu.m, or less than 2 .mu.m.
40. The oral pharmaceutical composition according to claim 34,
wherein the composition releases more than 50% of isotretinoin in
15 minutes in a 900 ml of media with a pH of 7.8 rotating at a 100
rpm in USP Type I apparatus.
41. An oral pharmaceutical composition according to claim 34
wherein the composition has a mean fed/fasted ratio of C.sub.max of
about 1.10.
42. An oral pharmaceutical composition according to claim 34
wherein the has a mean fed/fasted ratio of AUC.sub.0-t of about
1.26.
Description
FIELD OF THE INVENTION
[0001] The present invention provides an oral pharmaceutical
composition of isotretinoin with a reduced food effect. The present
invention further relates to a process for preparing the oral
pharmaceutical composition of the present invention.
BACKGROUND OF THE INVENTION
[0002] Isotretinoin is a retinoid (also known as 13-cis retinoic
acid). Owing to its low water solubility, the oral bioavailability
of isotretinoin is low. PCT Publication No. WO 00/25772 discloses
that the presently marketed formulation of isotretinoin, i.e.,
Accutane.RTM., contains isotretinoin at a mean particle size of
about 100 .mu.m resulting in only 20% oral bioavailability.
Therefore, this application discloses a formulation of isotretinoin
having a reduced particle size, thereby enhancing the oral
bioavailability.
[0003] U.S. Pat. Nos. 7,435,427 and 8,367,102 cover the marketed
formulation of Absorica . These patents disclose capsules
comprising a semi-solid suspension of isotretinoin containing at
least two lipidic excipients, one having an HLB value equal to or
greater than 10 and the other being an oily vehicle. These patents
are based on the use of the "Lidose technology" to provide a
formulation of isotretinoin with enhanced bioavailability.
[0004] The oral bioavailability of a drug is affected by various
factors, which include aqueous solubility, absorption of drug
through gastrointestinal tract, first pass effect, or food effect.
The "food effect" as used herein means food-drug interactions which
either decrease or increase the extent of drug absorption.
Isotretinoin is known to have a food effect, i.e., its absorption
is dependent on the presence of the food in the stomach. Therefore,
there is a need to develop a composition of isotretinoin which
exhibits a reduced food effect.
SUMMARY OF THE INVENTION
[0005] The present invention provides an oral pharmaceutical
composition comprising isotretinoin wherein said composition
exhibits a reduced food effect. The present invention further
provides an oral pharmaceutical composition comprising:
[0006] a) isotretinoin;
[0007] b) one or more surfactants having HLB value of 10 or
greater; and
[0008] c) one or more co-solvents wherein said composition is
substantially free of oil.
[0009] The present composition is in the form of a dispersion which
is further filled into capsules. The present invention further
provides a process for preparing the oral pharmaceutical
composition of the present invention. It also provides a method of
treating acne by administering the oral pharmaceutical composition
of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0010] In one aspect, the present invention provides an oral
pharmaceutical composition comprising isotretinoin wherein said
composition exhibits a reduced food effect.
[0011] In one embodiment of the above aspect, said composition
exhibits reduced food effect in comparison to the marketed
Epuris.TM. capsules as indicated by higher C.sub.max and AUC in
fasting state.
[0012] In another embodiment of the above aspect, said composition
exhibits a mean C.sub.max under fasting condition which is about
1.9 times higher than the C.sub.max of Epuris.TM. capsules.
[0013] In another embodiment of the above aspect, said composition
exhibits a mean AUC under fasting condition which is about 1.7
times higher than the AUC of Epuris.TM. capsules.
[0014] In another embodiment of the above aspect, the composition,
when administered orally, has a mean fed/fasted ratio of AUC of
about 1.26 and a mean fed/fasted ratio of C.sub.max of about
1.10.
[0015] In another aspect, the present invention provides an oral
pharmaceutical composition comprising:
[0016] a) isotretinoin;
[0017] b) one or more surfactants having HLB value of 10 or
greater; and
[0018] c) one or more co-solvents wherein said composition is
substantially free of oil.
[0019] In one embodiment of the above aspect, said composition
comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg
to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.
[0020] In another embodiment of the above aspect, said composition
comprises isotretinoin in an amount of about 40 mg.
[0021] In another embodiment of the above aspect, said composition
comprises isotretinoin in an amount of about 36 mg.
[0022] In another embodiment of the above aspect, said composition
comprises isotretinoin in an amount of about 32 mg.
[0023] In another embodiment of the above aspect, said composition
comprises isotretinoin in an amount of about 16 mg.
[0024] In one embodiment of the above aspect, said surfactants
include, but are not limited to, polysorbates prepared from lauric,
palmitic, stearic, and oleic acid; polyoxyethylene monoesters such
as polyoxyethylethylene monostearate, polyoxyethylene monolaurate,
and polyoxyethylene monooleate; polyethoxylated castor oils (e.g.,
Cremophor.RTM. EL 35); polyethylene glycol glycerides (e.g.,
Gelucire.RTM. 44/14); vitamin E TPGS; dioctyl sodium
sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures
thereof.
[0025] In another embodiment of the above aspect, the surfactant is
present in an amount of about 1% w/w to about 99% w/w by total
weight of the composition; preferably in an amount of about 10% w/w
to about 80% w/w by total weight of the composition; more
preferably in an amount of about 30% w/w to about 80% w/w by total
weight of the composition.
[0026] In another embodiment of the above aspect, said co-solvents
include, but are not limited to, propylene glycol, polypropylene
glycol, polyethylene glycols, diethyleneglycol monoethyl ether,
glyceryl caprylate, capric/caprylic glyceride, and mixtures
thereof.
[0027] In another embodiment of the above aspect, the composition
further comprises an antioxidant.
[0028] The antioxidant includes, but is not limited to, butylated
hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl
palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite,
sodium thiosulfate, propyl gallate, and mixtures thereof.
[0029] In one embodiment of the above aspect, the oral
pharmaceutical composition is in the form of a dispersion which is
further filled into capsules.
[0030] In yet another embodiment of the above aspect, the
composition comprises isotretinoin wherein the particle size
distribution of isotretinoin is such that D.sub.90 is less than 60
.mu.m, less than 55 .mu.m, less than 50 .mu.m, less than 45 .mu.m,
less than 40 .mu.m, less than 35 .mu.m, less than 30 .mu.m, less
than 25 .mu.m, less than 20 .mu.m, less than 15 .mu.m, or less than
10 .mu.m.
[0031] In yet another embodiment of the above aspect, the
composition comprises isotretinoin wherein the particle size
distribution of isotretinoin is such that D.sub.90 is less than 30
.mu.m.
[0032] In another embodiment of the above aspect, the composition
comprises isotretinoin wherein the particle size distribution of
isotretinoin is such that D.sub.50 is less than 40 .mu.m, less than
35 .mu.m, less than 30 .mu.m, less than 25 .mu.m, less than 20
.mu.m, less than 15 .mu.m, or less than 10 .mu.m or less than 5
.mu.m.
[0033] In yet another embodiment of the above aspect, the
composition comprises isotretinoin wherein the particle size
distribution of isotretinoin is such that D.sub.50 is less than 15
.mu.m.
[0034] In another embodiment of the above aspect, the composition
comprises isotretinoin wherein the particle size distribution of
isotretinoin is such that D.sub.10 is less than 20 .mu.m, less than
18 .mu.m, less than 17 .mu.m, less than 15 .mu.m, less than 12
.mu.m, less than 10 .mu.m, less than 8 .mu.m, less than 7 .mu.m,
less than 5 .mu.m, or less than 2 .mu.m.
[0035] In yet another embodiment of the above aspect, the
composition comprises isotretinoin wherein the particle size
distribution of isotretinoin is such that D.sub.10 is less than 7
.mu.m.
[0036] In yet another embodiment of the above aspect, the oral
pharmaceutical composition comprises isotretinoin wherein the
particle size distribution of isotretinoin is such that D.sub.90 is
less than 60 .mu.m and D.sub.50 is less than 40 .mu.m.
[0037] In yet another embodiment of the above aspect, the oral
pharmaceutical composition comprises isotretinoin wherein the
particle size distribution of isotretinoin is such that D.sub.90 is
less than 60 .mu.m, D.sub.50 is less than 40 .mu.m, and D.sub.10 is
less than 20 .mu.m.
[0038] In yet another embodiment, said oral pharmaceutical
composition is stable when stored at 40.degree. C. and 75% relative
humidity or at 25.degree. C. and 60% relative humidity for a period
of at least three months or to the extent necessary for the use of
the composition.
[0039] In yet another aspect, there is provided a process for the
preparation of an oral pharmaceutical composition wherein the
process comprises:
[0040] (a) adding one or more of surfactants in a co-solvent or a
mixture of co-solvents;
[0041] (b) dispersing isotretinoin into the solution of step
(a);
[0042] (c) milling the dispersion of step (b) in a milling
apparatus; and
[0043] (d) filling the milled dispersion of step (d) into a
capsule.
[0044] In an embodiment of the above aspect, an antioxidant is
added in step (a) of the process.
[0045] In still another aspect, the present invention provides a
method of treating acne, musculoskeletal and connective tissue
inflammations, emphysema, ulcerating diseases, cervical tumors in
HIV positive women, lung cancer in smokers, skin cancer,
neuroblastoma, recurrent prostate cancer, leukemia, high-grade
glioma, head and neck cancers, multiple myeloma, gram-negative
folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis,
cutaneous lupus erythematosus, acne fulminans, squamous cell
carcinoma, or cutaneous photoaging by administering to the
individual in need thereof the oral pharmaceutical composition of
the present invention.
[0046] In one embodiment of the above aspect, the present invention
provides a method of treating acne by administering to the
individual in need thereof the oral pharmaceutical composition of
the present invention.
[0047] The term "isotretinoin" refers to isotretinoin in its
crystalline or amorphous form, its esters, salts, or derivatives
thereof.
[0048] The term "stable," as used herein, refers to chemical
stability, wherein not more than 1.5% w/w of total related
substances are formed on storage at accelerated conditions of
stability at 40.degree. C. and 75% relative humidity or at
25.degree. C. and 60% relative humidity for a period of at least
three months or to the extent necessary for use of the
composition.
[0049] The term "AUC" refers to the area under the time/plasma
concentration curve after administration of the pharmaceutical
composition. AUC.sub.0-infinity denotes the area under the plasma
concentration versus time curve from time 0 to infinity;
AUC.sub.0-t denotes the area under the plasma concentration versus
time curve from time 0 to time t.
[0050] The term "C.sub.max" refers to the maximum concentration of
isotretinoin in the blood following administration of the
pharmaceutical composition.
[0051] The term "t.sub.max" refers to the time in hours when
C.sub.max is achieved following administration of the
pharmaceutical composition.
[0052] The term "food effect" as used herein means food-drug
interactions which either decrease or increase the extent of drug
absorption. It refers to a relative difference in AUC, C.sub.max
and/or t.sub.max of a drug, when said drug or a formulation thereof
is administered orally to a human concomitantly with food or in a
fed state as compared to the same values when the same formulation
is administered in a fasted state or without food.
[0053] The term "D.sub.10" refers to the particle size of
isotretinoin where 10% (w/v) of the particles have a size less than
the defined D.sub.10 value; "D.sub.50" refers to the particle size
of isotretinoin where 50% (w/v) of the particles have a size less
than the defined D.sub.50 value; "D.sub.90" refers to the particle
size of isotretinoin where 90% (w/v) of the particles have a size
less than the defined D.sub.90 value.
[0054] "Defined D.sub.10 value/D.sub.50 value/D.sub.90 value"
refers to the values defined in the embodiments.
[0055] The term "substantially free of oil" includes the complete
absence of oil and the presence of less than 5% of oil.
[0056] The size reduction of isotretinoin is achieved by wet
milling the dispersion of isotretinoin in an oily vehicle or the
dispersion of isotretinoin in an aqueous medium using mechanical
means such as a ball mill, and media mills such as a sand mill,
DYNO.RTM.-mill, or a bead mill. The grinding media in these mills
can comprise spherical particles such as stainless steel beads or
zirconium oxide balls.
[0057] The invention may be further illustrated by the following
examples, which are for illustrative purposes only and should not
be construed as limiting the scope of the invention in any way.
EXAMPLES
Example 1
TABLE-US-00001 [0058] Ingredients Quantity (% w/w) Isotretinoin
6.61 Cremophor .RTM. EL 35 57.02 Tween .RTM. 80 3.30 Butylated
hydroxy toluene 0.09 Propyl gallate 0.05 Propylene glycol 23.96
Vitamin E TPGS 8.92
Procedure:
[0059] 1. Cremophor.RTM. EL 35, Tween.RTM. 80, and propylene glycol
were mixed in a stainless steel vessel. [0060] 2. Butylated hydroxy
toluene and propyl gallate were added to the mixture of step 1.
[0061] 3. Isotretinoin was dispersed under stirring into the
mixture of step 2. [0062] 4. The dispersion of step 3 was milled in
a Dyno.RTM.-Mill containing zirconium beads to achieve a particle
size of isotretinoin such that D.sub.90 was about 22 .mu.m. [0063]
5. Vitamin E TPGS was melted at a temperature not exceeding
80.degree. C. [0064] 6. The milled dispersion of step 4 was heated
to below 50.degree. C. under continuous stirring. [0065] 7. The
melted vitamin E TPGS of step 5 was added under stirring to the
heated milled dispersion of step 6. [0066] 8. The dispersion of
step 7 was filled into capsules.
Example 2
TABLE-US-00002 [0067] Ingredients Quantity (% w/w) Isotretinoin
5.40 Cremophor .RTM. EL 35 46.62 Tween .RTM. 80 2.70 Butylated
hydroxy toluene 0.07 Propyl gallate 0.04 Propylene glycol 19.59
Vitamin E TPGS 7.29 Gelucire .RTM. 44/14 18.24
Procedure:
[0068] 1. Cremophor.RTM. EL 35, Tween.RTM. 80, and propylene glycol
were mixed in a stainless steel vessel. [0069] 2. Butylated hydroxy
toluene and propyl gallate were added to the mixture of step 1.
[0070] 3. Isotretinoin was dispersed under stirring into the
mixture of step 2. [0071] 4. The dispersion of step 3 was milled in
a Dyno.RTM.-Mill containing zirconium beads to achieve a particle
size of isotretinoin such that D.sub.90 was about 22 .mu.m. [0072]
5. Vitamin E TPGS was melted at a temperature not exceeding
80.degree. C. [0073] 6. The milled dispersion of step 4 was heated
to below 50.degree. C. with continuous stirring. [0074] 7. The
melted vitamin E TPGS of step 5 was added under stirring to the
heated milled dispersion of step 6. [0075] 8. Gelucire.RTM. 44/14
was melted at a temperature not exceeding 80.degree. C. and added
under stirring to the dispersion of step 7. [0076] 9. The
dispersion of step 8 was filled into capsules.
Dissolution Studies
[0077] The pharmaceutical composition of Example 2 (Test; 40 mg of
isotretinoin) was compared with the marketed formulation of
isotretinoin (Reference; 40 mg Epuris.TM. capsules) for the release
profile in the FDA recommended dissolution medium as given
below:
TABLE-US-00003 Dissolution Media 0.05M buffer pH 7.8 with 0.5% w/v
N,N- dimethyl dodecylamine N-oxide Apparatus/RPM/Vol USP Type I (20
mesh basket)/100/900 mL % of Drug Released in time (minutes) Sample
15 30 45 60 90 120 180 Test 84 94 94 94 95 97 98 Reference 1 9 24
49 89 100 100
[0078] From the above data, it is evident that the test product has
a better dissolution profile in comparison to the reference
product.
Pharmacokinetic Study Under Fed Condition
[0079] The pharmaceutical composition of Example 2 (Test; 40 mg of
isotretinoin) was compared with the marketed formulation of
isotretinoin (Reference; 40 mg Epuris.TM. capsules) under fed
conditions on 18 healthy adult male subjects, out of these, 15
subjects completed all the three periods of the study.
[0080] Values for various pharmacokinetic parameters, including
observed C.sub.max, AUC.sub.0-t and AUC.sub.0-inf were calculated
and are provided in Table 1 below.
TABLE-US-00004 TABLE 1 Comparative pharmacokinetic data for test
(T) and reference (R) in 15 healthy adult human male subjects: In
C.sub.max In AUC.sub.0-t In AUC.sub.0-inf Ratio (T/R) 111.56 106.31
106.67 90% CI 100.31-124.07 101.7-111.12 102.3-111.22
[0081] Average t.sub.max values for the Test and Reference were
3.6443 hours and 6.1444 hours, respectively. [0082] Under fed
conditions, the Test prototype showed a comparable behavior to the
Reference product (Epuris.TM.) in terms of both rate and extent of
absorption. The T/R ratios and 90% CIs for all PK parameters are
within the acceptable limits of 80% to 125%.
Pharmacokinetic Study Under Fasting Condition
[0083] The pharmaceutical composition of Example 2 (Test; 40 mg of
isotretinoin) was compared with the marketed formulation of
isotretinoin (Reference; 40 mg Epuris.TM. capsules) under fasting
conditions in 18 healthy adult male subjects, out of these 14
subjects completed all the three periods of the study.
[0084] Values for various pharmacokinetic parameters, including
observed C.sub.max, AUC.sub.0-t and AUC.sub.0-inf were calculated
and are provided in Table 2 below:
TABLE-US-00005 TABLE 2 Comparative pharmacokinetic data for Test
(T) vs Reference (R) in 14 healthy adult human male subjects: In
C.sub.max In AUC.sub.0-t In AUC.sub.0-inf Ratio 193.23 179.26
175.24 (T/R) 90% CI 157.56-236.98 156.77-204.98 154.3-199.01
[0085] Test has shown 1.9-fold higher C.sub.max and 1.7-fold higher
AUC as compared to Reference under fasting condition.
The Effect of Food on the Test Formulation of Example 2 (40 mg
Capsules) was also Evaluated and Results are Provided in Table 3
Below: [0086] Reference (R): Epuris.TM. 40 mg capsules. [0087] Test
(T): Isotretinoin 40 mg capsules (Example 2).
TABLE-US-00006 [0087] TABLE 3 Relative effect of food (Calculated
in number of fold (fed/fasting)) Formulation C.sub.max AUC.sub.0-t
Test (T fed/fast) 1.10 1.26 Reference (R fed/fast) 1.95 2.12
Above Data Indicates the Following:
[0088] For Test prototype the AUC under fed condition is
approximately 1.26-fold the value observed under fasting condition,
whereas C.sub.max under fed condition is approx. 1.1-fold higher as
compared to fasting condition. [0089] For Epuris.TM., both AUC and
C.sub.max under fed condition are .about.2-fold higher than under
fasted condition.
Example 3
TABLE-US-00007 [0090] Ingredients Quantity (% w/w) Isotretinoin
5.00 Cremophor .RTM. EL 35 37.50 Tween .RTM. 80 4.37 Butylated
hydroxy anisole 0.12 Propylene glycol 18.12 Vitamin E TPGS 12.50
Gelucire .RTM. 44/14 22.43
Procedure:
[0091] 1. Cremophor.RTM. EL 35, Tween.RTM. 80, and propylene glycol
were mixed in a stainless steel vessel. [0092] 2. Butylated hydroxy
anisole was added to the mixture of step 1. [0093] 3. Isotretinoin
was dispersed under stirring into the mixture of step 2. [0094] 4.
The dispersion of step 3 was milled in a Dyno.RTM.-Mill containing
zirconium beads to achieve a particle size of isotretinoin such
that D.sub.90 was about 22 .mu.m. [0095] 5. Vitamin E TPGS was
melted at a temperature not exceeding 80.degree. C. [0096] 6. The
milled dispersion of step 4 was heated to below 50.degree. C. with
continuous stirring. [0097] 7. The melted vitamin E TPGS of step 5
was added under stirring to the heated milled dispersion of step 6.
[0098] 8. Gelucire.RTM. 44/14 was melted at a temperature not
exceeding 80.degree. C. and added under stirring to the dispersion
of step 7. [0099] 9. The dispersion of step 8 was filled into
capsules.
Example 4
TABLE-US-00008 [0100] Ingredients Quantity (% w/w) Isotretinoin
5.40 Cremophor .RTM. EL 35 46.62 Tween .RTM. 80 2.70 Butylated
hydroxy toluene 0.07 Propyl gallate 0.04 Propylene glycol 9.795
Polyethylene glycol 9.795 Vitamin E TPGS 7.29 Gelucire .RTM. 44/14
18.24
Procedure:
[0101] 1. Cremophor.RTM. EL 35, Tween.RTM. 80, polyethylene glycol,
and propylene glycol were mixed in a stainless steel vessel. [0102]
2. Butylated hydroxy tolune and propyl gallate were added to the
mixture of step 1. [0103] 3. Isotretinoin was dispersed under
stirring into the mixture of step 2. [0104] 4. The dispersion of
step 3 was milled in a Dyno.RTM.-Mill containing zirconium beads to
achieve a particle size of isotretinoin such that D.sub.90 was
about 22 .mu.m. [0105] 5. Vitamin E TPGS was melted at a
temperature not exceeding 80.degree. C. [0106] 6. The milled
dispersion of step 4 was heated to below 50.degree. C. with
continuous stirring. [0107] 7. The melted vitamin E TPGS of step 5
was added under stirring to the heated milled dispersion of step 6.
[0108] 8. Gelucire.RTM. 44/14 was melted at a temperature not
exceeding 80.degree. C. and added under stirring to the dispersion
of step 7. [0109] 9. The dispersion of step 8 was filled into
capsules.
Example 5
TABLE-US-00009 [0110] Ingredients Quantity (% w/w) Isotretinoin
5.41 Cremophor .RTM. EL 35 46.63 Tween .RTM. 80 2.70 Butylated
hydroxy toluene 0.08 Propyl gallate 0.05 Propylene glycol 9.80
Polyethylene glycol 9.80 Vitamin E TPGS 7.30 Gelucire .RTM. 44/14
18.24
Procedure
[0111] 1. Cremophor.RTM. EL 35, Tween.RTM. 80, polyethylene glycol,
Gelucire.RTM. 44/14, vitamin E TPGS, and propylene glycol were
mixed in a stainless steel vessel with gentle heating below
50.degree. C. [0112] 2. Butylated hydroxy tolune and propyl gallate
was added to the mixture of step 1. [0113] 3. Isotretinoin was
dispersed under stirring into the mixture of step 2. [0114] 4. The
dispersion of step 3 was milled in a Dyno.RTM.-Mill containing
zirconium beads to achieve a particle size of isotretinoin such
that D.sub.90 was about 10 .mu.m. [0115] 5. The dispersion of step
4 was filled into capsules.
* * * * *